OncoSec Medical Inc. Names Adil Daud, M.D. As Chief Clinical Strategist
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Adil Daud, M.D. as Chief Clinical Strategist.
Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory Board and serves as Principal Investigator for OncoSec’s Phase 2 melanoma study.
Help employers find you! Check out all the jobs and post your resume.